% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • lsddc07 lsddc07 Feb 21, 2013 7:04 AM Flag

    Earnings release is here and looks good IMO

    Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2012
    Total GAAP revenue for 2012 was $267.7 million; pro forma revenue (including ex-US ZEVALIN® and FOLOTYN® for the entire year) was $302 million.
    GAAP Product revenues were up 41% and net income increased by 95% in 2012.
    The Company reported GAAP Diluted EPS of $1.46 and Non-GAAP Diluted EPS of $1.42 compared to last year GAAP EPS of $0.84 and non-GAAP of $1.31.
    FUSILEV® unit volume was higher in the fourth quarter compared to the third quarter and end user sales trends are stable year-to-date.
    Significant cost synergies have been achieved in a short period following the Allos acquisition. FOLOTYN® shows strong sales growth in the most recent quarter.
    The Company ended the year with a strong balance sheet with $143 million in cash, cash equivalents and investments after paying $133 million for the Allos acquisition, net of Allos’ cash.
    The Company expects revenues and operating income to increase in 2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
6.87+0.05(+0.73%)Jul 29 4:00 PMEDT